The so-called NewCo model of value creation has been around for years, but its use with assets connected to China appears to be increasing, as the world’s second-most populous country experiences a renaissance in its drug development industry.
A new flavor of company is shaking up how biotechs are built.
Instead of launching with eye-popping early-stage science or a new platform, there’s a …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Bristol Myers’ alliance with Hengrui ranks as the second-largest licensing pact of its kind since the start of 2025, trailing…
Executives seek “skin in the game” despite signs of a stock market cooldown.
After years of buying licences for foreign-made medicines, Chinese biotech firms are now profiting handsomely from their own…
Chinese companies dominate global gene therapy competition with 48 programs vs 20 in US, targeting expensive Western treatments…
Such deals allow Chinese firms to profit while minimising capital outlays, but also carry risks, law firm says.
China is becoming a leader in biotech innovation. That offers hope to rare disease patients and presents a problem to American…
Biotech M&A is accelerating. Track the deals that are happening here.
